Coya Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON, TX, 77024
Mailing Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON, TX, 77024
Phone
650.739.3939
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 16, 2026 | View on SEC |
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | March 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 30, 2026 | View on SEC |
| 8-K Current report of material events | January 30, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 28, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
| 4 Insider stock transaction report | January 26, 2026 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Pioneering Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
- Lead candidate COYA 302 is in Phase 2 clinical trials for ALS and FTD.
Material Events
8-K
Leadership Change
April 2, 2026
Medium Impact
- Planned leadership transition signals shift from discovery to commercial readiness
- Appointment of Mark H. Pavao, an Amgen veteran with 30+ years of industry experience
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.